Vaccine Therapies in Malignant Glioma

Taemin Oh, Eli T. Sayegh, Shayan Fakurnejad, Daniel Oyon, Jonathan Balquiedra Lamano, Joseph David Di Domenico, Orin Bloch, Andrew T. Parsa

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Glioblastoma is a grade IV astrocytoma that is widely accepted in clinical neurosurgery as being an extremely lethal diagnosis. Long-term survival rates remain dismal, and even when tumors undergo gross resection with confirmation of total removal on neuroimaging, they invariably recur with even greater virulence. Standard therapeutic modalities as well as more contemporary treatments have largely resulted in disappointing improvements. However, the therapeutic potential of vaccine immunotherapy for malignant glioma should not be underestimated. In contrast to many of the available treatments, vaccine immunotherapy is unique because it offers the means of delivering treatment that is highly specific to both the patient and the tumor. Peptide, heat-shock proteins, and dendritic cell vaccines collectively encapsulate the majority of research efforts involving vaccine-based treatment modalities. In this review, important recent findings for these vaccine types are discussed in the context of ongoing clinical trials. Broad challenges to immunotherapy are also considered.

Original languageEnglish (US)
JournalCurrent Neurology and Neuroscience Reports
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Active Immunotherapy
Glioma
Vaccines
Immunotherapy
Glioblastoma
Therapeutics
Neurosurgery
Heat-Shock Proteins
Neuroimaging
Dendritic Cells
Virulence
Neoplasms
Survival Rate
Clinical Trials
Peptides
Research

Keywords

  • Glioblastoma
  • Glioma
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Oh, T., Sayegh, E. T., Fakurnejad, S., Oyon, D., Lamano, J. B., Di Domenico, J. D., ... Parsa, A. T. (2015). Vaccine Therapies in Malignant Glioma. Current Neurology and Neuroscience Reports, 15(1). https://doi.org/10.1007/s11910-014-0508-y

Vaccine Therapies in Malignant Glioma. / Oh, Taemin; Sayegh, Eli T.; Fakurnejad, Shayan; Oyon, Daniel; Lamano, Jonathan Balquiedra; Di Domenico, Joseph David; Bloch, Orin; Parsa, Andrew T.

In: Current Neurology and Neuroscience Reports, Vol. 15, No. 1, 01.01.2015.

Research output: Contribution to journalReview article

Oh, T, Sayegh, ET, Fakurnejad, S, Oyon, D, Lamano, JB, Di Domenico, JD, Bloch, O & Parsa, AT 2015, 'Vaccine Therapies in Malignant Glioma', Current Neurology and Neuroscience Reports, vol. 15, no. 1. https://doi.org/10.1007/s11910-014-0508-y
Oh T, Sayegh ET, Fakurnejad S, Oyon D, Lamano JB, Di Domenico JD et al. Vaccine Therapies in Malignant Glioma. Current Neurology and Neuroscience Reports. 2015 Jan 1;15(1). https://doi.org/10.1007/s11910-014-0508-y
Oh, Taemin ; Sayegh, Eli T. ; Fakurnejad, Shayan ; Oyon, Daniel ; Lamano, Jonathan Balquiedra ; Di Domenico, Joseph David ; Bloch, Orin ; Parsa, Andrew T. / Vaccine Therapies in Malignant Glioma. In: Current Neurology and Neuroscience Reports. 2015 ; Vol. 15, No. 1.
@article{a48eef8bf5494f70af22e383c1864e50,
title = "Vaccine Therapies in Malignant Glioma",
abstract = "Glioblastoma is a grade IV astrocytoma that is widely accepted in clinical neurosurgery as being an extremely lethal diagnosis. Long-term survival rates remain dismal, and even when tumors undergo gross resection with confirmation of total removal on neuroimaging, they invariably recur with even greater virulence. Standard therapeutic modalities as well as more contemporary treatments have largely resulted in disappointing improvements. However, the therapeutic potential of vaccine immunotherapy for malignant glioma should not be underestimated. In contrast to many of the available treatments, vaccine immunotherapy is unique because it offers the means of delivering treatment that is highly specific to both the patient and the tumor. Peptide, heat-shock proteins, and dendritic cell vaccines collectively encapsulate the majority of research efforts involving vaccine-based treatment modalities. In this review, important recent findings for these vaccine types are discussed in the context of ongoing clinical trials. Broad challenges to immunotherapy are also considered.",
keywords = "Glioblastoma, Glioma, Immunotherapy, Vaccine",
author = "Taemin Oh and Sayegh, {Eli T.} and Shayan Fakurnejad and Daniel Oyon and Lamano, {Jonathan Balquiedra} and {Di Domenico}, {Joseph David} and Orin Bloch and Parsa, {Andrew T.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s11910-014-0508-y",
language = "English (US)",
volume = "15",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Vaccine Therapies in Malignant Glioma

AU - Oh, Taemin

AU - Sayegh, Eli T.

AU - Fakurnejad, Shayan

AU - Oyon, Daniel

AU - Lamano, Jonathan Balquiedra

AU - Di Domenico, Joseph David

AU - Bloch, Orin

AU - Parsa, Andrew T.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Glioblastoma is a grade IV astrocytoma that is widely accepted in clinical neurosurgery as being an extremely lethal diagnosis. Long-term survival rates remain dismal, and even when tumors undergo gross resection with confirmation of total removal on neuroimaging, they invariably recur with even greater virulence. Standard therapeutic modalities as well as more contemporary treatments have largely resulted in disappointing improvements. However, the therapeutic potential of vaccine immunotherapy for malignant glioma should not be underestimated. In contrast to many of the available treatments, vaccine immunotherapy is unique because it offers the means of delivering treatment that is highly specific to both the patient and the tumor. Peptide, heat-shock proteins, and dendritic cell vaccines collectively encapsulate the majority of research efforts involving vaccine-based treatment modalities. In this review, important recent findings for these vaccine types are discussed in the context of ongoing clinical trials. Broad challenges to immunotherapy are also considered.

AB - Glioblastoma is a grade IV astrocytoma that is widely accepted in clinical neurosurgery as being an extremely lethal diagnosis. Long-term survival rates remain dismal, and even when tumors undergo gross resection with confirmation of total removal on neuroimaging, they invariably recur with even greater virulence. Standard therapeutic modalities as well as more contemporary treatments have largely resulted in disappointing improvements. However, the therapeutic potential of vaccine immunotherapy for malignant glioma should not be underestimated. In contrast to many of the available treatments, vaccine immunotherapy is unique because it offers the means of delivering treatment that is highly specific to both the patient and the tumor. Peptide, heat-shock proteins, and dendritic cell vaccines collectively encapsulate the majority of research efforts involving vaccine-based treatment modalities. In this review, important recent findings for these vaccine types are discussed in the context of ongoing clinical trials. Broad challenges to immunotherapy are also considered.

KW - Glioblastoma

KW - Glioma

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84937125925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937125925&partnerID=8YFLogxK

U2 - 10.1007/s11910-014-0508-y

DO - 10.1007/s11910-014-0508-y

M3 - Review article

C2 - 25431096

AN - SCOPUS:84937125925

VL - 15

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 1

ER -